Approaches to NSCLC With or Without Targetable Mutations

In this podcast, we will explore approaches to non-small cell lung cancer (NSCLC) with and without targetable mutations. NSCLC is the most common type of lung cancer, and while significant strides have been made in its management, there are still areas of unmet need. Our speakers, Luis Raez, MD, FACP, FCCP, from Memorial Healthcare System in Pembroke Pines, FL, Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, and Jorge Nieva, MD, from the University of California, San Francisco, CA, share the current treatment landscape for patients with NSCLC with and without targetable mutations, highlighting recent trial results, and challenges associated with sequencing of therapies.